gemcitabine has been researched along with thiazolidines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Yao, D; Zheng, Q; Zhou, T | 1 |
| Choi, KY; Han, G; Lee, SH; Ryu, WJ | 1 |
2 other study(ies) available for gemcitabine and thiazolidines
| Article | Year |
|---|---|
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammasomes; Interleukin-1beta; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Thiazolidines; Thiones; Triple Negative Breast Neoplasms; Up-Regulation; Wnt Signaling Pathway | 2020 |
Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Neoplasm Metastasis; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines; Wnt Signaling Pathway | 2021 |